Statins as a novel therapeutic strategy in acute lung injury.
Statins as a novel therapeutic strategy in acute lung injury.
复制标题
DOI：
10.4103/2045-8932.105028
复制
发表时间：
2012-10
影响因子：
2.6
通讯作者：
Jacobson JR
中科院分区：
文献类型：
--
作者：
Singla S;Jacobson JR
急性肺损伤(ALI)是一种与肺部和全身炎症相关的破坏性临床疾病，其特征是肺微血管屏障功能不全，最终导致非心源性肺水肿。通过研究他汀类药物在相关细胞和动物模型中的作用，有助于理解ALI中内皮屏障功能障碍的机制。这些药物的许多多效性，包括对内皮细胞(EC)细胞骨架重排、NADPH氧化酶和一氧化氮活性的直接影响，以及对EC基因差异表达的影响，与ALI的病理生物学相关，并提示他汀类药物在这方面具有潜在的治疗作用。此外，临床前研究和对相关患者群体的观察结果支持他汀类药物在ALI中的保护潜力，为现在的决定性临床试验铺平了道路。
Acute lung injury (ALI) is a devastating clinical condition associated with pulmonary and systemic inflammation and characterized by incompetence of the pulmonary microvascular barrier culminating in noncardiogenic pulmonary edema. An understanding of the mechanisms underlying endothelial barrier dysfunction in ALI has been facilitated by study of the effects of statins in relevant cellular and animals models. Many of the pleotropic properties of these drugs, including direct effects on endothelial cell (EC) cytoskeletal rearrangement, NADPH oxidase, and nitric oxide activity, as well as effects on differential EC gene expression, are relevant to the pathobiology of ALI and suggest a potential therapeutic role for statins in this context. Moreover, results from preclinical studies and observations in relevant patient populations support the protective potential of statins in ALI, paving the way now for definitive clinical trials.